Komori
Ridge-i (5572) · InitiativeRestated

Continuing R&D activities

First written in FY2023-Q3. 9 of 10 entries say "Restated". Latest entry: FY2026.

10entries
4years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2023-Q3 – FY20262023: 320232024: 320242025: 220252026: 22026
Same theme, other companies
Continuation of R&D activities with no change in statusA theme 192 companies write about · 0 as a headwind · 181 as a tailwind

96 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 192 companies compared. The sentences above are computed from all 192.
Full recordFilings, disclosures and news, newest first
  1. FY2026RestatedAnnual report

    「The research objective is primarily the use of LLMs and generative AI, and the company has begun receiving inquiries and commissioned projects from customers involving these technologies.」

    Research and development aimed at using LLMs and generative AI, as well as discussions with customers leading to consulting and contracted projects, continued. Research and development expenses were ¥32.462 million.
  2. FY2026-H1RestatedAnnual report

    「Research and development expenses for the 6-month interim consolidated accounting period were ¥20.294 million. There were no material changes in the status of research and development activities during the interim consolidated accounting period.」

    The company disclosed that there were no material changes in its research and development activities and that research and development expenses were ¥20.294 million.
  3. FY2025RestatedAnnual report

    「The research objective is primarily the use of LLMs and generative AI, and the company has begun receiving inquiries and commissioned projects from customers involving these technologies.」

    Research and development focused on LLMs and generative AI, together with related customer inquiries and commissioned projects, continues.
  4. FY2025-H1RestatedAnnual report

    「Research and development expenses for the 6-month interim consolidated accounting period were ¥18.282 million. There were no material changes in the status of research and development activities during the interim consolidated accounting period.」

    The company disclosed that there were no material changes in its research and development activities and that research and development expenses for the interim consolidated accounting period were ¥18.282 million.
  5. FY2024RestatedAnnual report

    「The objective of the research is to use LLMs and generative AI, and the company has begun receiving inquiries and commissioned projects from customers involving these technologies. Within the company, engineers in the development department form project teams for each research objective and conduct research and development with support from technical advisers.」

    The research focus is explicitly identified as the use of LLMs and generative AI, and the research and development structure supporting customer inquiries and commissioned projects remains in place. Research and development expenses were ¥47.290 million.
  6. FY2024-Q3RestatedAnnual report

    「Research and development expenses for the 9-month period ended in the third quarter were ¥34.939 million. There were no material changes in the status of research and development activities during the 9-month period ended in the third quarter.」

    The company disclosed continued research and development activities and research and development expenses of ¥34.939 million.
  7. FY2024-Q2RestatedAnnual report

    「Research and development expenses for the 6-month period ended in the second quarter were ¥27.656 million. There were no material changes in the status of research and development activities during the 6-month period ended in the second quarter.」

    The company disclosed continued research and development activities and research and development expenses of ¥27.656 million.
  8. FY2024-Q1RestatedAnnual report

    「Research and development expenses for the 3-month period ended in the first quarter were ¥18.537 million. There were no material changes in the status of research and development activities during the 3-month period ended in the first quarter.」

    The company disclosed continued research and development activities and research and development expenses of ¥18.537 million for the quarter.
  9. FY2023RestatedAnnual report

    「Based on its management policy of “taking on unresolved challenges and creating a new society by using cutting-edge technologies and business expertise powered by data and AI,” the company is engaged in joint research and the development of joint businesses with universities and other research institutions, with the aim of implementing advanced technologies, including AI and deep learning, in society.」

    Joint research and joint business development aimed at implementing advanced technologies in society continued, with research and development expenses of ¥52.687 million disclosed for the fiscal year.
  10. FY2023-Q3First statedAnnual report

    「Research and development expenses for the 9-month period ended in the third quarter were ¥13.338 million. There were no material changes in the status of research and development activities during the 9-month period ended in the third quarter.」

    The company reports continued research and development activities and expenses for the year-to-date period.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Ridge-i yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Continuing R&D activities | Ridge-i Inc. (5572) | Komori